Novabiosis Inc. and Promethera Therapeutics Joint Release

Promethera Therapeutics SA, a pioneer in cell therapies for treatment of severe liver diseases, has divested certain assets of their US subsidiary, Promethera Biosciences, LLC.
With our OPO partners we can help improve access to non-transplantable organs and more
The latest news and development of Novabiosis and research community
View our calendar for upcoming events and important announcements
For more information about our primary cell products & services contact our customer support team
Through our extensive partnerships with U.S. Organ Procurement Organizations (OPO’s), we offer an allocation service to safely provide non-transplantable human organs for research purposes.
Download a complete Inventory list to review for easy to use reference when placing an order.
Insights to the research industry and current news for research cells discovery and success.
Promethera Therapeutics SA, a pioneer in cell therapies for treatment of severe liver diseases, has divested certain assets of their US subsidiary, Promethera Biosciences, LLC.
Copyright © 2023 Novabiosis | All Rights Reserved.